Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Most common adverse events at all doses: Nausea (3355%, dose-related) Vomiting (1335%) Decreased appetite (1528%) Constipation or diarrhea (1020%) Injection-site reaction (510%) Dose-related dysesthesia signal: The TRIUMPH-4 trial identified a dose-related dysesthesia (nerve-tingling, paresthesia) signal: This is the most-flagged trial-level safety signal for retatrutide and the reason community doses cluster at 2-4 mg/week well below where the dysesthesia signal becomes prominent
Metabolism 56 , 8793 (2007)
It is a cytoskeletal protein that may serve as a signal-responsive link between the dynamic cortical actin cytoskeleton and regions of membrane dynamics such as neurite-outgrowth processes and synaptic plasticity [32]
(2015) 6-month trial at doses up to 1,000 mg/day reported no significant adverse events [12]
Researchers investigate GHK-Cu for its involvement in copper-associated signaling pathways, gene-expression regulation, extracellular matrix biology, and cellular communication processes
US$ 29.50
US$ 24.95
US$ 24.40
